CIAM
PTGX icon

Caitong International Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Caitong International Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41
Closed -$2.27K – 2397
2025
Q2 		$2.27K Sell
41
-2,747
-99% -$132K ﹤0.01% 1343
2025
Q1 		$135K Buy
+2,788
New +$117K 0.1% 203

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caitong International Asset Management's PTGX Position: Q3 2025 in Review

Caitong International Asset Management sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 41 shares — an estimated $2.27K sold.

Caitong International Asset Management first reported a position in PTGX in Q1 2025 and held it in 2 quarters. The position peaked at $135K in Q1 2025. 275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Caitong International Asset Management reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 41 Protagonist Therapeutics shares in Q3 2025, an estimated $2.27K.
  • Caitong International Asset Management first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 2 quarters.
  • Caitong International Asset Management's Protagonist Therapeutics position peaked at $135K in Q1 2025.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Caitong International Asset Management's 13F filing for Q3 2025, filed 19 Nov 2025.